aristolochic acid i has been researched along with Disease Exacerbation in 18 studies
aristolochic acid I: phospholipase A inhibitor
aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our findings demonstrate the first that AA could induce secretion and expression of fibrogenic leptin in kidney fibroblasts, which reveal potential involvement of leptin in the progression of kidney fibrosis in aristolochic acid nephropathy." | 3.77 | The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast. ( Hsu, SL; Lee, TC; Lin, TC; Yang, CS, 2011) |
| "Renal failure was in progression since Pcreat was 2." | 2.68 | Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. ( Abramowicz, D; Depierreux, M; Tielemans, C; Vanherweghem, JL, 1996) |
| "As most patients progress to ESRD, need for renal replacement therapy, as either dialysis or kidney transplant, usually ensues." | 2.52 | Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. ( Luciano, RL; Perazella, MA, 2015) |
| " The chronic AAN patients took the lowest AA-I dose per day but with the longest period and the highest cumulative dosage and exhibited a very large range of eGFR changing rate (from -21." | 1.38 | Aristolochic acid nephropathy: variation in presentation and prognosis. ( Cai, SQ; Li, XM; Meng, LQ; Su, T; Wang, HY; Wang, X; Yang, L; Zou, WZ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Luciano, RL | 1 |
| Perazella, MA | 1 |
| Weidemann, DK | 1 |
| Weaver, VM | 1 |
| Fadrowski, JJ | 1 |
| Liu, X | 1 |
| Liu, Y | 1 |
| Cheng, M | 1 |
| Xiao, H | 1 |
| Lu, H | 1 |
| Chen, B | 1 |
| Hong, W | 1 |
| Liang, Y | 1 |
| Bai, Y | 1 |
| Chen, H | 2 |
| Cao, G | 1 |
| Chen, DQ | 1 |
| Wang, M | 1 |
| Vaziri, ND | 1 |
| Zhang, ZH | 1 |
| Mao, JR | 1 |
| Bai, X | 1 |
| Zhao, YY | 1 |
| Kong, PI | 1 |
| Chiu, YW | 1 |
| Kuo, MC | 1 |
| Chen, SC | 1 |
| Chang, JM | 1 |
| Tsai, JC | 1 |
| Hwang, SJ | 1 |
| Chen, HC | 1 |
| Pozdzik, AA | 1 |
| Berton, A | 1 |
| Schmeiser, HH | 1 |
| Missoum, W | 1 |
| Decaestecker, C | 1 |
| Salmon, IJ | 1 |
| Vanherweghem, JL | 2 |
| Nortier, JL | 1 |
| Lin, TC | 1 |
| Lee, TC | 1 |
| Hsu, SL | 1 |
| Yang, CS | 1 |
| Yang, L | 2 |
| Su, T | 1 |
| Li, XM | 1 |
| Wang, X | 1 |
| Cai, SQ | 1 |
| Meng, LQ | 1 |
| Zou, WZ | 1 |
| Wang, HY | 1 |
| Fragiadaki, M | 1 |
| Witherden, AS | 1 |
| Kaneko, T | 1 |
| Sonnylal, S | 1 |
| Pusey, CD | 1 |
| Bou-Gharios, G | 1 |
| Mason, RM | 1 |
| Chen, D | 1 |
| Tang, Z | 1 |
| Luo, C | 1 |
| Liu, Z | 2 |
| Lee, S | 1 |
| Lee, T | 1 |
| Lee, B | 1 |
| Choi, H | 1 |
| Yang, M | 1 |
| Ihm, CG | 1 |
| Kim, M | 1 |
| Wu, Y | 1 |
| Hu, W | 1 |
| Li, L | 1 |
| Li, X | 1 |
| Wang, H | 1 |
| Abramowicz, D | 1 |
| Tielemans, C | 1 |
| Depierreux, M | 1 |
| Nishimagi, E | 1 |
| Kawaguchi, Y | 1 |
| Terai, C | 1 |
| Kajiyama, H | 1 |
| Hara, M | 1 |
| Kamatani, N | 1 |
| Guitouni, O | 1 |
| Karimi, I | 1 |
| Kazmouhi, L | 1 |
| Berrekchi, FZ | 1 |
| Bekkaoui, S | 1 |
| Benabdellah, N | 1 |
| Elyoubi, R | 1 |
| Souaaid, S | 1 |
| Abda, N | 1 |
| Bentata, Y | 1 |
| Van Ypersele De Strihou, C | 1 |
| Jadoul, M | 1 |
3 reviews available for aristolochic acid i and Disease Exacerbation
| Article | Year |
|---|---|
Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment.
Topics: Animals; Aristolochia; Aristolochic Acids; Disease Progression; Glucocorticoids; Humans; Kidney Dise | 2015 |
Toxic environmental exposures and kidney health in children.
Topics: Adolescent; Aristolochic Acids; Child; Disease Progression; Dysuria; Environmental Exposure; Humans; | 2016 |
Progressive interstitial renal fibrosis due to Chinese herbs in a patient with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome.
Topics: Aristolochic Acids; Biopsy; Chromatography, High Pressure Liquid; CREST Syndrome; Disease Progressio | 2001 |
1 trial available for aristolochic acid i and Disease Exacerbation
| Article | Year |
|---|---|
Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy.
Topics: Aristolochic Acids; Case-Control Studies; Disease Progression; Drugs, Chinese Herbal; Female; Fibros | 1996 |
14 other studies available for aristolochic acid i and Disease Exacerbation
| Article | Year |
|---|---|
Acute nephrotoxicity of aristolochic acid in vitro: metabolomics study for intracellular metabolic time-course changes.
Topics: Aristolochia; Aristolochic Acids; Biomarkers; Cell Line; Chromatography, High Pressure Liquid; Disea | 2016 |
Transforming growth factor-β1 stimulates hedgehog signaling to promote epithelial-mesenchymal transition after kidney injury.
Topics: Animals; Aristolochic Acids; Cell Line; Disease Models, Animal; Disease Progression; Epithelial-Mese | 2016 |
Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression.
Topics: Adenine; Animals; Aristolochic Acids; Biomarkers; Disease Models, Animal; Disease Progression; Early | 2016 |
Aristolochic acid nephropathy due to herbal drug intake manifested differently as Fanconi's syndrome and end-stage renal failure--a 7-year follow-up.
Topics: Adult; Aristolochic Acids; Chromatography, High Pressure Liquid; Diagnosis, Differential; Disease Pr | 2008 |
Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity?
Topics: Adaptive Immunity; Adult; Aged; Aristolochic Acids; Case-Control Studies; Disease Progression; Drugs | 2010 |
The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast.
Topics: Animals; Aristolochic Acids; Carcinogens; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; Disease | 2011 |
Aristolochic acid nephropathy: variation in presentation and prognosis.
Topics: Aristolochic Acids; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Diseases; Male; M | 2012 |
Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo.
Topics: Animals; Aristolochic Acids; Biomarkers; Blood Urea Nitrogen; Cadherins; Collagen Type I; Connective | 2011 |
Clinical and pathological spectrums of aristolochic acid nephropathy.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aristolochic Acids; Biomarkers; Biopsy; Chi-Square Dis | 2012 |
Fanconi's syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid.
Topics: Adult; Aristolochic Acids; Disease Progression; Drugs, Chinese Herbal; Fanconi Syndrome; Female; Hum | 2004 |
Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy.
Topics: Acute Disease; Adult; Aged; Aristolochic Acids; Cell Proliferation; Child; Chronic Disease; Disease | 2005 |
Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis.
Topics: Actins; Adult; Aristolochic Acids; Biomarkers; Biopsy; Connective Tissue Growth Factor; Disease Prog | 2007 |
Consumption of nephrotoxic plants among chronic hemodialysis patients in the Eastern region of Morocco: A multicentric cross-sectional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aristolochia; Child; Cross-Sectional Studies; Disease Pr | 2022 |
Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose.
Topics: Aristolochia; Disease Progression; Humans; Medicine, Chinese Traditional; Phytotherapy; Renal Insuff | 2002 |